Lacy John M, Wilson William A, Bole Raevti, Chen Li, Meigooni Ali S, Rowland Randall G, Clair William H St
Department of Urology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
Department of Radiation Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
Prostate Cancer. 2016;2016:9561494. doi: 10.1155/2016/9561494. Epub 2016 Mar 22.
Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41-1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others.
目的。在本研究中,我们评估了在先前行近距离放射治疗后发现生化复发后进行挽救性近距离放射治疗的经验。方法和材料。从2001年到2012年,在肯塔基大学或其他中心接受近距离放射治疗的21名患者出现生化失败且无转移证据。对计算机断层扫描(CT)进行评估;前列腺植入剂量不足的患者考虑重新植入。结果。本研究中的大多数患者(61.9%)为低风险,挽救前中位前列腺特异性抗原(PSA)为3.49(范围17.41 - 1.68)。平均随访时间为61个月。在重新植入后的最后随访中,21例中有11例(52.4%)无生化复发。低风险患者生化复发-free有下降趋势(p = 0.12)。国际前列腺症状评分(IPSS)在3个月随访时升高,但在18个月时下降且与基线评分相当。结论。原发性近距离放射治疗后进行挽救性近距离放射治疗是可行的;然而,根据我们的经验,第二次近距离放射治疗后的副作用比第一次近距离放射治疗后更高。在这组患者中我们证明,大约有50%的肿瘤控制率,低风险患者似乎比其他患者有更好的结果。